Cargando…
QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2
A dataset of seventy-two (72) cytotoxic compounds of the National Cancer Institute (NCI) was studied by QSAR and docking approaches to gain deeper insights into ligands selectivity on SK-MEL-2 cell line. The QSAR model was built using fifty (50) molecules and the best-generated model based on multip...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110328/ https://www.ncbi.nlm.nih.gov/pubmed/32258485 http://dx.doi.org/10.1016/j.heliyon.2020.e03640 |
_version_ | 1783513030369214464 |
---|---|
author | Umar, Abdullahi Bello Uzairu, Adamu Shallangwa, Gideon Adamu Uba, Sani |
author_facet | Umar, Abdullahi Bello Uzairu, Adamu Shallangwa, Gideon Adamu Uba, Sani |
author_sort | Umar, Abdullahi Bello |
collection | PubMed |
description | A dataset of seventy-two (72) cytotoxic compounds of the National Cancer Institute (NCI) was studied by QSAR and docking approaches to gain deeper insights into ligands selectivity on SK-MEL-2 cell line. The QSAR model was built using fifty (50) molecules and the best-generated model based on multiple linear regression showed, respectively good quality of fits ([Formula: see text] (0.864), [Formula: see text] (0.845), Q(2)(cv) (0.799) and [Formula: see text] (0.706)). The model's predictive ability was determined by a test set of twenty-two (22) compounds. Compounds 30 and 41 were selected as templates for in silico design because they had high pGI(50) activity and are in the model's applicability domain. The obtained information from the model was explored to design novel molecules by introducing various modifications. Moreover, the designed compounds with better-predicted activity (pGI(50)) values were selected and docked on the active site of the protein (PDB-CODE: 3OG7) which is responsible for melanoma cancer to elucidate their binding mode. AN2 (−12.1kcalmol(-1)) and AC4 (−12.4kcalmol(-1)) showed a better binding score for the target when compared with (vemurafenib, −11.3kcalmol(-1)) the known inhibitor of the target (V600E-BRAF). These findings may be very helpful in early anti-cancer drug development. |
format | Online Article Text |
id | pubmed-7110328 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-71103282020-04-03 QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2 Umar, Abdullahi Bello Uzairu, Adamu Shallangwa, Gideon Adamu Uba, Sani Heliyon Article A dataset of seventy-two (72) cytotoxic compounds of the National Cancer Institute (NCI) was studied by QSAR and docking approaches to gain deeper insights into ligands selectivity on SK-MEL-2 cell line. The QSAR model was built using fifty (50) molecules and the best-generated model based on multiple linear regression showed, respectively good quality of fits ([Formula: see text] (0.864), [Formula: see text] (0.845), Q(2)(cv) (0.799) and [Formula: see text] (0.706)). The model's predictive ability was determined by a test set of twenty-two (22) compounds. Compounds 30 and 41 were selected as templates for in silico design because they had high pGI(50) activity and are in the model's applicability domain. The obtained information from the model was explored to design novel molecules by introducing various modifications. Moreover, the designed compounds with better-predicted activity (pGI(50)) values were selected and docked on the active site of the protein (PDB-CODE: 3OG7) which is responsible for melanoma cancer to elucidate their binding mode. AN2 (−12.1kcalmol(-1)) and AC4 (−12.4kcalmol(-1)) showed a better binding score for the target when compared with (vemurafenib, −11.3kcalmol(-1)) the known inhibitor of the target (V600E-BRAF). These findings may be very helpful in early anti-cancer drug development. Elsevier 2020-03-27 /pmc/articles/PMC7110328/ /pubmed/32258485 http://dx.doi.org/10.1016/j.heliyon.2020.e03640 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Umar, Abdullahi Bello Uzairu, Adamu Shallangwa, Gideon Adamu Uba, Sani QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2 |
title | QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2 |
title_full | QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2 |
title_fullStr | QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2 |
title_full_unstemmed | QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2 |
title_short | QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2 |
title_sort | qsar modelling and molecular docking studies for anti-cancer compounds against melanoma cell line sk-mel-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110328/ https://www.ncbi.nlm.nih.gov/pubmed/32258485 http://dx.doi.org/10.1016/j.heliyon.2020.e03640 |
work_keys_str_mv | AT umarabdullahibello qsarmodellingandmoleculardockingstudiesforanticancercompoundsagainstmelanomacelllineskmel2 AT uzairuadamu qsarmodellingandmoleculardockingstudiesforanticancercompoundsagainstmelanomacelllineskmel2 AT shallangwagideonadamu qsarmodellingandmoleculardockingstudiesforanticancercompoundsagainstmelanomacelllineskmel2 AT ubasani qsarmodellingandmoleculardockingstudiesforanticancercompoundsagainstmelanomacelllineskmel2 |